Market Research Logo

Global ENT Disorder Treatment Market 2017-2021

Global ENT Disorder Treatment Market 2017-2021

About ENT Disorder Treatment

ENT also known as otolaryngology, is an area of medicine that deals with disorders of ear, nose, and throat. Dysfunction of these body parts can affect quality of life and in certain cases may even lead to medical emergency. The market encompasses drugs that are used for the treatment of the ENT disorder. It mainly considers the various drug class used for the treatment of numerous symptoms of the disease. The major ENT disorders included in the report are rhinitis, sinusitis, otitis media, and tonsillitis.

Technavio’s analysts forecast the global ENT disorder treatment market to grow at a CAGR of 2.17% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global ENT disorder treatment market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales from both branded and generic drugs.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global ENT Disorder Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • ALK
  • GSK
  • Novartis
  • Sanofi
Other prominent vendors
  • Allergan
  • AstraZeneca
  • Dr. Reddy's Laboratories
  • Lupin
  • Merck
  • Mylan
  • Otonomy
  • Pfizer
  • Sun Pharma
  • Teva Pharmaceuticals
Market driver
  • Deteriorating environmental conditions.
  • For a full, detailed list, view our report
Market challenge
  • Growing cases of anti-bacterial resistance.
  • For a full, detailed list, view our report
Market trend
  • Growing consolidation in industry particularly for rhinitis.
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global ENT Disorder Treatment Market 2017-2021

Technavio recognizes the following companies as the key players in the global ENT disorder treatment market: ALK, GSK, Novartis, and Sanofi.

Other Prominent Vendors in the market are: Allergan, AstraZeneca, Dr. Reddy's Laboratories, Lupin, Merck, Mylan, Otonomy, Pfizer, Sun Pharma, and Teva Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “One trend in market is increase in research on allergic disorders. Allergic diseases such as rhinitis, if not managed properly, have chances of developing into organizations around the world are working to have a better understanding of the pathogenesis of allergic diseases. For instance, The Australasian Society of Clinical Immunology and Allergy, Allergy and Anaphylaxis Australia, and the European Academy of Allergy and Clinical Immunology are working for a better understanding of allergic diseases.”

According to the report, one driver in market is deteriorating environmental conditions. Deteriorating environmental conditions is one of the major reasons for the rising prevalence of ENT disorders such as rhinitis. For instance, perennial allergic rhinitis can prevail around the year and is often the result of sensitivity to mold on wallpaper, pet hair, carpeting, houseplants, and upholstery. Also, congested living conditions and high pollution levels are known to be some of the primary factors leading to sinusitis. Studies have suggested that allergic rhinitis can be aggravated by certain polluting agents such as automobile engine emission. The problem is more severe in urban areas specifically in developing countries like India and China. It is estimated that more than three-fourth of the urban population is exposed to the air quality that exceeds the WHO limits.

Further, the report states that one challenges in market is growing cases of anti-bacterial resistance. Antimicrobial resistance is one of the major public health challenges faced globally, and has been accelerated by the overuse of antibiotics across the globe. Overprescribing antibiotics is a common problem in primary care, where most of the infections are caused by viruses. It is estimated that general practitioners prescribe 90% of the total antibiotic prescriptions, where respiratory tract infections and respiratory disorders are the major causes of prescription. Per the data provided by the CDC more than two million people worldwide, each year, are identified as being antibiotic resistant. Antibiotic resistance adds avoidable and considerable cost on the already overburdened healthcare system. As per the CDC, antibiotic resistance is estimated to have an economic burden of $55 billion on the US per year. The CDC indicates that about 235 million antibiotic doses are administered per year, of these 20%-50% are not needed.

Companies Mentioned

ALK, GSK, Novartis, Sanofi, Allergan, AstraZeneca, Dr. Reddy's Laboratories, Lupin, Merck, Mylan, Otonomy, Pfizer, Sun Pharma, and Teva Pharmaceuticals.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Key market highlights
  • Disease overview
    • Table Some major treatments associated with sinusitis
  • Market landscape
    • Market overview
      • Table Snapshot: Global ENT disorder treatment market
      • Table Global ENT disorder treatment market 2016-2021 ($ millions)
      • Table Opportunity analysis: Global ENT disorder treatment market
    • Five forces analysis
      • Table Five forces analysis
  • Pipeline landscape
    • Table Key pipeline by vendors
    • Table Pipeline landscape
  • Market segmentation by disease
    • Table Global ENT disorder treatment market segmentation by disease type
    • Table Market snapshot: Global ENT disorder market by disease type 2016-2021
    • Global rhinitis treatment market
      • Table Types of rhinitis
      • Table Major types of allergic rhinitis
      • Table Global rhinitis treatment market 2016-2021 ($ millions)
    • Global sinusitis treatment market
      • Table Types of sinusitis
      • Table Some drugs approved for sinusitis
      • Table Global sinusitis treatment market 2016-2021 ($ millions)
    • Global otitis media treatment market
      • Table Otitis media therapy in pipeline
      • Table Global otitis media treatment market 2016-2021 ($ millions)
    • Global tonsillitis treatment market
      • Table Global tonsillitis treatment market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table ENT disorder treatment market by geography 2016 and 2021
    • Table ENT disorder treatment market by geography 2016-2021 ($ millions)
    • ENT disorder treatment market in Americas
      • Table Market scenario in Americas
      • Table ENT disorder treatment market in Americas 2016-2021 ($ millions)
    • ENT disorder treatment market in EMEA
      • Table Market scenario in EMEA
      • Table ENT disorder treatment market in EMEA 2016-2021 ($ millions)
    • ENT disorder treatment market in APAC
      • Table Market scenario in APAC
      • Table ENT disorder treatment market in APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table ENT disorders triggered by various pollutants
      • Table Adult population with sinusitis and chronic rhinitis in US 2014 (million)
    • Impact of drivers on key customer segments
      • Table Impact of drivers
    • Market challenges
      • Table Antibiotic resistance development steps
      • Table Few landmark generic version of branded drugs
    • Impact of challenges on key customer segments
      • Table Impact of challenges
  • Market trends
    • Growing consolidation in industry particularly for rhinitis
    • Increase in research on allergic disorders
    • Awareness about controlled usage of antibiotics
      • Table Major causes of antibiotic resistance
  • Vendor landscape
    • Competitive landscape
      • Table Competitive structure analysis of global ENT disorder treatment market 2016
      • Table Competitive analysis of global ENT disorder treatment market
  • Key vendor analysis
    • ALK
      • Table ALK: Key highlights
      • Table ALK: Strength assessment
      • Table ALK: Strategy assessment
      • Table ALK: Opportunity assessment
    • GSK
      • Table GSK: Key highlights
      • Table GSK: Strength assessment
      • Table GSK: Strategy assessment
      • Table GSK: Opportunity assessment
      • Table GSK: YoY growth rate of Avamys/Veramyst 2014 and 2015 ($ millions)
    • Novartis
      • Table Novartis: Key highlights
      • Table Novartis: Strength assessment
      • Table Novartis: Strategy assessment
      • Table Novartis: Opportunity assessment
    • Sanofi
      • Table Sanofi: Key highlights
      • Table Sanofi: Strength assessment
      • Table Sanofi: Strategy assessment
      • Table Sanofi: Opportunity assessment
      • Table Sanofi: YoY growth rate of Allegra 2014 and 2015 ($ millions)
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report